Literature DB >> 8013490

Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients.

W V Kern1, A Markus, E Andriof.   

Abstract

Two patients with acute leukemia developed Escherichia coli bacteremia while receiving oral ofloxacin for antibacterial prophylaxis during profound neutropenia. The isolates were resistant to ofloxacin (MIC 25 and 12.5 micrograms/ml respectively), other fluoroquinolones and several unrelated agents. Whole cell drug accumulation studies with four different fluoroquinolones suggested major differences between drugs but only minor alterations in individual drug permeability in the two resistant isolates compared with a susceptible control strain. In a supercoiling assay using the purified DNA gyrase and plasmid pBR322, high concentrations (> or = 250 micrograms/ml) of both ofloxacin and ciprofloxacin were needed for visible inhibition of enzyme activity suggesting mutations in the DNA gyrase gene as the significant mechanism of resistance in both strains.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013490     DOI: 10.1007/bf01982191

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Resistance to beta-lactam antibiotics and ciprofloxacin in gram-negative bacilli and staphylococci isolated from blood: a European collaborative study. European Study Group on Antibiotic Resistance.

Authors:  K Dornbusch
Journal:  J Antimicrob Chemother       Date:  1990-08       Impact factor: 5.790

2.  Accumulation of enoxacin by Escherichia coli and Bacillus subtilis.

Authors:  J Bedard; S Wong; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

3.  Norfloxacin resistance in a clinical isolate of Escherichia coli.

Authors:  H Aoyama; K Sato; T Kato; K Hirai; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

4.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.

Authors:  N Moniot-Ville; J Guibert; N Moreau; J F Acar; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

5.  Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

Authors:  M López-Brea; T Alarcón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

6.  The accumulation of five quinolone antibacterial agents by Escherichia coli.

Authors:  J M Diver; L J Piddock; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-03       Impact factor: 5.790

7.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.

Authors:  K Hirai; H Aoyama; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

8.  Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli.

Authors:  K Sato; Y Inoue; T Fujii; H Aoyama; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 9.  Mode of action of the new quinolones: new data.

Authors:  D C Hooper; J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

10.  Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones.

Authors:  H Aoyama; K Sato; T Fujii; K Fujimaki; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

View more
  4 in total

1.  The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.

Authors:  Toshiro Mizuno; Noriyuki Katsumata; Hirofumi Mukai; Chikako Shimizu; Masashi Ando; Toru Watanabe
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

2.  Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

Authors:  N Lehn; J Stower-Hoffmann; T Kott; C Strassner; H Wagner; M Kronke; W Schneider-Brachert
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

Authors:  C Peña; J M Albareda; R Pallares; M Pujol; F Tubau; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 4.  Host impairments in patients with neoplastic diseases.

Authors:  J Peter Donnelly; Nicole M A Blijlevens; Walter J F M van der Velden
Journal:  Cancer Treat Res       Date:  2014
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.